Orphazyme delays annual report again after striking deal with Kempharm

Orphazyme has provided yet another new date for the release of its 2021 annual report, following the biotech firm’s deal to sell its business to Kempharm. Almost three months have passed since the original release date.
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

Orphazyme, a listed company in Denmark that has been restructuring since March, has postponed its annual report for 2021 yet again, a company press release states.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading